Skip to content

The Mayo Clinic Neuroimmunology Laboratory

Dr. Sean Pittock The Mayo Clinic’s Neuroimmunology Laboratory leading expert
Dr. Sean Pittock
Dr. John Chen The Mayo Clinic’s Neuroimmunology Laboratory leading expert
Dr. John Chen
Dr. Eoin Flanagan The Mayo Clinic’s Neuroimmunology Laboratory leading expert
Dr. Eoin Flanagan

The Mayo Clinic’s Neuroimmunology Laboratory has some of the leading experts in MOG-AD and is a go-to place for patients to get some of the best care to manage their disease.  They developed one of the most accurate and widely used MOG Antibody blood tests and are continually moving research forward in this rare neuroimmune disease.

Recent Research at The Mayo Clinic

Dr. Sean Pittock, Dr. John Chen, and Dr. Eoin Flanagan have provided a list of Mayo Clinic publications from 2018 to the present including commentary in their words on the research.  These articles are provided with permission from The Mayo Clinic Neuroimmunology Laboratory.


Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management | Multiple Sclerosis and Neuroimmunology | Frontiers in Neurology

The understanding of MOGAD and knowledge of its clinical and imaging aspects and potentially beneficial treatments has rapidly expanded in recent years. This review article was undertaken to provide an update on how MOGAD should be diagnosed and to highlight the range of clinical and MRI features through illustrative tables and figures. We highlight the pitfall of low positive MOG-IgG results which can be encountered with other diseases and outline red flags that suggest an alternative diagnosis. Finally, we review the current acute and chronic management of MOGAD and emphasize the importance of upcoming prospective randomized placebo-controlled clinical trials of attack-prevention treatments in MOGAD which will guide our therapeutic approach into the future.   


Association of Maintenance Intravenous Immunoglobulin With Prevention of Relapse in Adult Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease | Clinical Pharmacy and Pharmacology | JAMA Neurology | JAMA Network

In this international collaborative retrospective study of IVIG for adult patients with MOG antibody-associated disease (MOGAD), we found maintenance IVIG was associated with a significant reduction in relapses.  More frequent relapses were seen in patients receiving lower or less frequent dosing of IVIG.  This dose response to IVIG helps support it is effective, but the ideal dose varies depending on the individual. 

OCT retinal nerve fiber layer thickness differentiates acute optic neuritis from MOG antibody-associated disease and Multiple Sclerosis: RNFL thickening in acute optic neuritis from MOGAD vs MS – ScienceDirect


This study looked at OCT during acute optic neuritis and found that MOGAD optic neuritis had more thickening of the peripapillary retinal nerve fiber layer thickness (pRNFL) than multiple sclerosis optic neuritis.  OCT can help differentiate these causes of optic neuritis before the antibody testing returns and can also be used to help confirm optic neuritis attacks for clinical practice and future clinical trials. 

Optic chiasm involvement in AQP-4 antibody–positive NMO and MOG antibody–associated disorder – Deena Tajfirouz, Tanyatuth Padungkiatsagul, Shannon Beres, Heather E Moss, Sean Pittock, Eoin Flanagan, Amy Kunchok, Shailee Shah, M Tariq Bhatti, John J Chen, 2022 (

This study found that the frequency of chiasmal involvement with optic neuritis was similar between AQP4+NMOSD (20%) and MOGAD (16%).  However, chiasmal involvement in MOGAD was more likely to be from a longitudinally extensive lesion affecting the entire optic nerve and chiasm while AQP4+NMOSD more commonly had isolated chiasmal involvement.

Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders | Neurology

This study looked at a series of MRI’s over time in patients with MOGAD, AQP4+NMOSD, and MS.  The MRI T2 lesions in MOGAD resolve completely more often than in AQP4+NMOSD and MS. This has implications for diagnosis, monitoring disease activity, and clinical trial design, while also providing insight into pathogenesis of CNS demyelinating diseases.

Brainstem and cerebellar involvement in MOG-IgG-associated disorder versus aquaporin-4-IgG and MS | Journal of Neurology, Neurosurgery & Psychiatry (

This study looked at the clinical and radiologic involvement of the brainstem and/or cerebellar involvement in MOGAD and found that they were common, but more likely to occur as part of a multifocal central nervous system attack rather than in isolation. 

CNS Demyelinating Attacks Requiring Ventilatory Support With Myelin Oligodendrocyte Glycoprotein or Aquaporin-4 Antibodies | Neurology

This study compared the frequency of attacks requiring ventilatory support in MOGAD vs AQP4+NMOSD.  Attacks requiring ventilatory support were similarly rare in patients with MOGAD (2.9%) and AQP4+NMOSD (2.2%).  AQP4+NMOSD patients were on the ventilatory longer than MOGAD patients. All patients with MOGAD recovered, but 2 of 11 (18%) patients with AQP4-NMOSD died of the attack.


Variability of cerebrospinal fluid findings by attack phenotype in myelin oligodendrocyte glycoprotein-IgG-associated disorder – ScienceDirect

This study looked at 203 lumbar punctures that were done in MOGAD patients and found that elevated white blood cells was seen less commonly with isolated optic neuritis (23%), compared to myelitis, brain/brainstem attacks, or combinations thereof (>70%). Abnormal CSF oligoclonal bands ranged from 1% (optic neuritis) to 18% (brain/brainstem attacks).

Frequency and characteristics of MRI-negative myelitis associated with MOG autoantibodies – Elia Sechi, Karl N Krecke, Sean J Pittock, Divyanshu Dubey, A Sebastian Lopez-Chiriboga, Amy Kunchok, Brian G Weinshenker, Nicholas L Zalewski, Eoin P Flanagan, 2021 (

This study found that the initial spinal cord MRI was negative in 7/73 (10%) MOGAD patients, despite severe acute disability and myelitis symptoms/signs (paraparesis, neurogenic bladder, sensory level, Lhermitte’s phenomenon). Myelitis lesions became visible in follow-up MRI in three patients. A negative spinal cord MRI should not dissuade from MOG-IgG testing in patients with acute/subacute myelitis.

Positive Predictive Value of Myelin Oligodendrocyte Glycoprotein Autoantibody Testing | Demyelinating Disorders | JAMA Neurology | JAMA Network

In this study, we assessed Mayo Clinic patients who underwent MOG IgG testing over the course of 2 years (2018 to 2019) and assessed the positive predictive value,  false-positive rate and specificity.  We found the antibody was highly specific (97.8%) but false positives occurred in up to a quarter of patients. The false positives were more frequent with low titers (of 1:20-1:40) and when the antibody was ordered in very low probability situations.  The major message is that MOG IgG testing should be reserved for those with suspicious clinical and radiologic syndromes and caution is advised when low titer results are found in patients with atypical features.

 We studied the long-term clinical outcomes in 29 patients with myelin oligodendrocyte glycoprotein (MOG) antibody associated disorders (MOGAD with follow up of 9 years or more. The median follow-up duration was 14 years (range, 9-31). The median EDSS at last follow-up was 2 (range, 0-10) which is consistent with mild disability. Patients did develop additional mild disability with subsequent attacks, supporting the rationale for studies of attack prevention treatments in MOGAD. No patients had a secondary progressive disease course. In summary, we found most MOGAD patients had a favorable long-term outcome without secondary progression despite frequent relapses. This differs from the outcome reported with MS and aquaporin-4-IgG neuromyelitis optica spectrum disorders (NMOSD). This study looked at the efficacy of steroid-sparing maintenance immunotherapy for patients with relapsing MOGAD.  Rituximab, azathioprine, mycophenolate, and regular IVIG all led to a reduction in attacks, while traditional multiple sclerosis treatments were ineffective.  Among these treatments, monthly IVIG appeared to be the most efficacious in reducing relapses. It is important to note that only patients with relapsing disease typically require chronic immunotherapy.  The most common first line therapies for relapsing MOGAD patients are rituximab, azathioprine, or mycophenolate, but if the patient relapses despite these treatments, a change to monthly IVIG may be helpful.

This study looked at the population-based etiologies of optic neuritis using the Rochester Epidemiology Project.  5% of optic neuritis was caused by MOGAD in the predominantly white population of Olmsted County, MN.  Other causes of optic neuritis were multiple sclerosis in 57%, idiopathic in 29%, and AQP4-IgG positive NMOSD in 3%.

This study reports two patients with multiple relapses and poor outcome with MOGAD and highlights some of the MRI findings of brain thinning.

The 2015 diagnostic criteria for NMOSD was created before the appreciation of MOGAD as a distinct disorder.  This study looked at 170 MOGAD patients seen at the Mayo Clinic and found that only 43 (25%) fulfilled the 2015 seronegative NMOSD criteria.  This highlights that the NMOSD criteria fails to capture the majority of MOGAD patients and supports specific molecular biomarker-associated diagnostic criteria for inflammatory central nervous system disorders.

This study is the largest human pathological study of MOGAD that was done as a collaboration between Mayo Clinic and The University of Vienna. We defined the histopathology of 22 biopsies and 2 autopsies from patients with myelin oligodendrocyte glycoprotein (MOG) antibody associated disorders (MOGAD). MOGAD pathology is dominated by coexistence of both perivenous and confluent white matter demyelination, with an over-representation of intracortical demyelinated lesions compared to typical MS. Radially expanding confluent slowly expanding smoldering lesions in the white matter as seen in MS, are not present. A CD4+ T-cell dominated inflammatory reaction with granulocytic infiltration predominates. Complement deposition is present in all active white matter lesions, but a preferential loss of MOG is not observed. AQP4 is preserved. MOGAD is pathologically distinguished from AQP4-IgG seropositive NMOSD, but shares some overlapping features with MS. The results may have implications for future development of treatments in MOGAD.

In this study Mayo Clinic investigators showed that in up to 10% of patients with MOG-IgG myelitis, the initial MRI can be negative. Thus, a negative MRI spine should not dissuade from MOG-IgG testing in a patient with acute/subacute myelitis.

In this multicenter study of MOG-IgG cell-based assays (CBAs) involving Mayo Clinic and other international investigators, live MOG-IgG CBAs showed excellent agreement for high positive and negative samples at 3 international testing centers. Low positive samples were more frequently discordant than in a similar comparison of aquaporin-4 antibody assays. Further research is needed to improve international standardization for clinical care.

This study evaluated the frequency of having both MOG-IgG and AQP4-IgG positive in the same patient.  Among 15,598 patients tested for both MOG-IgG and AQP4-IgG, only 10 patients (0.06%) were positive for both.  When both were positive, the AQP4-IgG titers were typically much higher than the MOG-IgG and the clinical phenotype resembled AQP4-IgG positive NMOSD more than MOGAD.  This study demonstrates that co-positivity of both AQP4-IgG and MOG-IgG is quite rare.

This study retrospectively reviewed 173 MOGAD patients and found that 18 (10%) had symptoms of area postrema syndrome (intractable nausea, vomiting, and/or hiccups) that were typically in conjunction with other neurologic symptoms.  Only 1 (0.6%) MOGAD patient had isolated symptoms of area postrema syndrome, which is much less common than seen in AQP4-IgG positive NMOSD (9.4%–14.5%).

In this study, Mayo Clinic investigators report two patients with MOG-IgG antibody associated disorder who had unilateral hemi-encephalitis, a recently recognize syndrome associated with this antibody.

MOGAD often causes optic neuritis with perineural enhancement (inflammation of the optic nerve sheath and peribulbar fat).  This study reported 2 MOGAD patients that had optic perineuritis (inflammation of the optic nerve sheath) with sparing of the optic nerve.  Because MOGAD has a propensity to involve the optic nerve sheath, it is possible that many previous cases of “idiopathic” optic perineuritis may be explained by MOGAD.

In this international collaborative study including Mayo Clinic investigators this study showed that the live cell based MOG-IgG assay used at Mayo Clinic and Oxford was superior to the fixed cell based assay. An accompanying editorial highlighted the live-cell based assay, used at Mayo Clinic as being the gold standard for detecting MOG-IgG.

In this observational study of 54 patients with MOG-IgG myelitis, we showed it may mimic viral/post viral acute flaccid myelitis. Longitudinally extensive T2-hyperintense lesions are typical, but most patients have more than 1 lesion, and an H-shaped axial T2 pattern confined to gray matter and lack of enhancement are discriminating features from aquaporin-4–IgG and MS myelitis. Myelitis attacks are more severe than MS but recover better than AQP4-IgG positive neuromyelitis optica spectrum disorder. Recognition of the clinical and radiologic characteristics of MOG-IgG myelitis and its discriminators from other etiologies will help clinicians identify patients with myelitis in whom MOG-IgG should be tested.

In this study, Mayo Clinic investigators showed that the availability of MOG-IgG and Aquaporin-4-IgG allowed 12-14% of cases of transverse myelitis previously labelled idiopathic to be given a specific diagnosis. This highlighted the need to incorporate these biomarkers into future transverse myelitis diagnostic criteria.

In this collaborative study between Mayo Clinic Investigators and Sri Lanka, MOG-IgG was found in 17% of patients with inflammatory demyelinating diseases of the CNS and 3.5 times more common than AQP4-IgG.

This is one of the largest published cohorts of patients with MOG-IgG associated disorder (MOGAD) optic neuritis.  The study showed that MOGAD optic neuritis typically presents with severe vision loss, but recovery is much better than AQP4-IgG positive neuromyelitis optica spectrum disorder (NMOSD) optic neuritis.  Features of MOGAD optic neuritis are optic disc edema at onset (up to 86%), bilateral (50%), recurrent (50%), and perineural enhancement on MRI (50%). This study looked at MOGAD patients with acute disseminated encephalomyelitis (ADEM) and found that persistent MOG-IgG was associated with a higher chance of future relapse compared to patients that became seronegative.  Diagnostic criteria was also proposed for MOGAD as follows: Proposed Diagnostic Criteria for Myelin Oligodendrocyte Glycoprotein (MOG-IgG)–Associated Disordersa
  1. Laboratory findingb: serum positive for MOG-IgG by cell-based assayc
  2. Clinical findings: any of the following presentations:
    1. ADEM
    2. Optic neuritis, including CRION
    3. Transverse myelitis (ie, LETM or STM)
    4. Brain or brainstem syndrome compatible with demyelination
    5. Any combination of the above
  3. Exclusion of alternative diagnosis

Abbreviations: ADEM, acute demyelinating encephalomyelitis; CRION, chronic relapsing inflammatory optic neuropathy; LETM, longitudinally extensive transverse myelitis; STM, short-segment transverse myelitis.
a Must meet all 3 criteria.
b Transient seropositivity favors lower likelihood of relapse.
c In absence of serum, positivity in cerebrospinal fluid would allow fulfillment of criteria 1.

This study looked at a large cohort patients with recurrent optic neuritis and found that 13% were caused by MOGAD, 19% were caused by AQP4-IgG NMOSD, 19% were caused by multiple sclerosis, and 49% were “double negative” (cause is unknown).  MOGAD patients had frequent relapses, but retained good vision compared to AQP4-IgG NMOSD.

This study evaluated serum from 177 participants from the Optic Neuritis Treatment Trial that was completed in 1991 and found 3 (1.7%) were positive for MOG-IgG and no patients were positive for AQP4-IgG.  This low percentage of positivity was likely due to the inclusion criteria of the trial, which excluded patients with prior optic neuritis and bilateral optic neuritis.  Two of the three MOGAD patients had a relapse of optic neuritis in the 15 year follow-up period.  All 3 retained good visual acuity.

The following are review articles on MOGAD, which discuss how MOGAD differs from other demyelinating conditions, such as neuromyelitis optica spectrum disorder:

Gospe, Sidney M., John J. Chen, and M. Tariq Bhatti. “Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein associated disorder-optic neuritis: a comprehensive review of diagnosis and treatment.” Eye 35.3 (2021): 753-768.

Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein associated disorder-optic neuritis: a comprehensive review of diagnosis and treatment | Eye (


Sechi, Elia, and Eoin P. Flanagan. “Autoimmune Demyelinating Syndromes: Aquaporin-4-IgG-positive NMOSD and MOG-IgG Associated Disorder.” Neuroimmunology. Springer, Cham, 2021. 221-241.

Autoimmune Demyelinating Syndromes: Aquaporin-4-IgG-positive NMOSD and MOG – IgG Associated Disorder | SpringerLink


Redenbaugh V, Flanagan EP.  Monoclonal Antibody Therapies Beyond Complement for NMOSD and MOGAD. Neurotherapeutics. 2022 Mar 10. doi: 10.1007/s13311-022-01206-x.

Monoclonal Antibody Therapies Beyond Complement for NMOSD and MOGAD – PubMed (


Valencia-Sanchez C, Flanagan EP.  Uncommon inflammatory/immune-related myelopathies. J Neuroimmunol. 2021 Dec 15; 361:577750 Epub 2021 Oct 13 PMID: 34715593 DOI: 10.1016/j.jneuroim.2021.577750

Uncommon inflammatory/immune-related myelopathies – ScienceDirect


Chen, John J., et al. “Optic neuritis in the era of biomarkers.” Survey of Ophthalmology 65.1 (2020): 12-17.


Chen, John J., and M. Tariq Bhatti. “Clinical phenotype, radiological features, and treatment of myelin oligodendrocyte glycoprotein-immunoglobulin G (MOG-IgG) optic neuritis.” Current Opinion in neurology 33.1 (2020): 47-54.,_radiological_features,_and.9.aspx


Prasad, Sashank, and John Chen. “What you need to know about AQP4, MOG, and NMOSD.” Seminars in neurology. Vol. 39. No. 06. Thieme Medical Publishers, 2019.

Tajfirouz, Deena A., M. Tariq Bhatti, and John J. Chen. “Clinical Characteristics and Treatment of MOG-IgG–Associated Optic Neuritis.” Current neurology and neuroscience reports 19.12 (2019): 100.

Chen, John J., and Clare L. Fraser. “Do myelin oligodendrocyte glycoprotein antibodies represent a distinct syndrome?.” Journal of Neuro-Ophthalmology 39.3 (2019): 416-423.


Flanagan, Eoin P. “Neuromyelitis optica spectrum disorder and other non–multiple sclerosis central nervous system inflammatory diseases.” CONTINUUM: Lifelong Learning in Neurology 25.3 (2019): 815-844.

NOTE: This article is available through purchase, but may be requested.

Jim Broutman's Foundation at The Mayo Clinic

After a horrific and serious bout of optic neuritis and transverse myelitis which was attributed to the MOG Antibody, our own Chief Media Officer, Jim Broutman, with the help of Dr. Sean Pittock, set up his own foundation allowing people to donate directly to the Mayo Clinic Neuroimmune Research Laboratory specifically to support MOG-AD research.  If you would like to support this great effort in research, please follow the link below:

Join Jim Broutman in Supporting MOG IgG Associated Disorder Research at Mayo Clinic

Intrested in participating in research or a paying a clinical visit at The Mayo Clinic?

The Mayo Clinic Neuroimmunology Laboratory would like patients to know that while their departments have some limits on virtual new appointments as they want the doctors to see patients face to face as much as possible, there are some exceptions, so they will do everything they can to accommodate MOGAD patients.

The doctors think it would be best for you or your physician to contact their neurology/ophthalmology appointment centers via their website to request appointments.

If you have trouble getting through the standard appointment route or if you are interested in MOG-AD research, you can reach out to:

Melissa Bush
Ph: 507-538-5418

Massachusetts General Hospital
Harvard University

Michael Levy, MD, PhD

Dr. Levy is an Associate Professor in Neurology who was recently recruited to lead the new Neuroimmunology Division at the Massachusetts General Hospital. His mission is to build a combined clinical and research neuroimmunology program to develop therapies for patients with autoimmune diseases of the central nervous system. Dr. Levy moved from Baltimore, MD, where he was one of the faculty at Johns Hopkins University since 2009 and Director of the Neuromyelitis Optica Clinic.

Clinically, Dr. Levy specializes in taking care of children and adults with rare neuroimmunological diseases including neuromyelitis optica, transverse myelitis, MOG antibody disease and acute disseminated encephalomyelitis. In addition to four monthly clinics, Dr. Levy is the principal investigator on several clinical studies and drug trials for these conditions.

In the laboratory, Dr. Levy’s research focuses on four main areas:
1. Development of animal models of neuromyelitis optica (NMO) with the goal of tolerization as a sustainable long term treatment: His team generated a mouse model of NMO based on pathogenic T cells reactive against the aquaporin-4 water channel. Now, they are using this mouse model to create a tolerization therapy to desensitize the immune response to aquaporin-4.
2. Genetic basis of transverse myelitis: His team discovered a genetic mutation in VPS37a found in a group of patients with a familial form of transverse myelitis (TM). To understand how this gene is involved in this immune process, they generated a mouse model with this mutation.
3. The immunopathogenesis of MOG antibody disease: This may depend on a subset of T cells called gamma/delta T cells. These specialize T cells react to MOG in mouse models and attack the central nervous system. In addition to understanding why and how these T cells are involved in MOG antibody disease, they are developing a treatment to target these cells.
4. Biomarker assays for other autoimmune diseases of the central nervous system: They are developing assays that detect autoreactive T cells in NMO and MOG antibody disease. In parallel, they are screening for novel antibodies to glial cells in related disorders such as encephalitis and optic neuritis.

Executive Director
Executive Board Member

Julia Lefelar

After many years of occasional temporarily dimming vision and chronic fatigue, Julia had a series of acute attacks of optic neuritis in 2014 and was diagnosed with Neuromyelitis Optica Spectrum Disorder (NMOSD). However, once the MOG antibody live cell-based assay was available, she was diagnosed with MOG Antibody Disease (MOG-AD) in 2017. It was this long, emotionally painful journey through the unknown that inspired the start of The MOG Project. After looking for answers for so many years, Julia did not want anyone else to ever feel alone in the search for help. Julia has worked as a Software Engineer and Project Leader at the senior and principal levels for over 35 years. She uses her skills in project management to help organize the team’s activities and realize their goal to provide the most up-to-date information possible to those in need. She co-leads the Wings of Hope, MOG Sloggers Support Group and is a key driving force around the success of our projects.

Executive Board Member

Amy Ednie

Amy is a long-time advocate and volunteer for various non-profit and volunteer organizations. Her experience and passion to help this cause has been instrumental in the growth of this idea into a positive force and impact in the world of MOG-AD and rare disease.  She has over 25 years of successful leadership and global experience in an operations, consulting, sales, and marketing capacity (Unisys, Oracle, Illumina).  She has an earned reputation for defining goals and objectives and creating action plans to accomplish those goals. She keeps us honest with practical advice and coaching and isn’t afraid to tackle the unknown with her connections, research and hands on approach to ‘get it done’. 

Director of MOG-AD Resources and Advocacy
Executive Board Member

Peter Fontanez

Peter is a firefighter paramedic near Orlando, Florida. His daughter, Isabel, was diagnosed with ADEM in February of 2016 which sent her to the hospital PICU. After almost making a complete recovery, she had a relapse of Multiphasic Acute Disseminated Encephelomyelitis (ADEM) with Optic Neuritis (ON) causing her to be hospitalized again. After a 2nd relapse, she was diagnosed with MOG-AD. He and his wife Pamela, along with their son Israel, have banded together to help Isabel and others who suffer with MOG and ADEM learn more about these diseases and help to further push research efforts. Together, he and Pam are proud of their incredibly close family that supports each other and loves to spend time together. 

Director of Pediatric Research Advocacy
Executive Board Member

Jen Gould

Jen joined The MOG Project in late 2018. Her daughter, Sophia, was diagnosed with MOG-AD in January 2018 after a bout of encephalitis, followed by optic neuritis. Jen’s area of focus is pediatric MOG and helping fellow parents navigate this condition to find their new normal. She lives in Raleigh, NC with her husband, Mark and their two children Sophia and Sebastian.

Director of Blind Resources
Executive Board Member

Andrea Mitchell

Andrea Mitchell has had relapsing form of MOG-AD since October 2011. It took 2 years for her to find the right diagnosis and due to a lack of aggressive treatment, she lost the sight in both of her eyes. MOG-AD has also affected her hearing and bladder. She often suffers from daily pain all over her body and continually fights off fatigue. She has a very loving and supportive husband named James. They have a sweet Pekingese by the name of Bubba and a loving retired guide dog named Newcastle. They have a beautiful yellow lab named Indy and he is Andrea’s new guide dog since October 2021. Her passion is to educate, empower, promote advocacy and support others dealing with this rare condition. She enjoys helping those who are newly blind find resources for gaining their independence. As an Executive Board Member for The MOG Project, she assists in providing educational materials, conducts support groups and connects with others through social media and email inquiries. Her husband James is passionate about advocacy in the caregiver role. They currently live in the San Francisco Bay Area located in northern California.

Digital Marketing & Media Consultant
Advisory Board Member

Kristina Lefelar

Kristina is a graduate of Towson University, where she achieved Summa Cum Laude honors in Psychology and Communications. She was a member of Pi Kappa Delta Honors Society, National Speech & Debate Association and The National Society of Collegiate Scholars. Kristina works as an Account Manager at a marketing agency, managing consumer brands’ affiliate marketing programs in various industries (Fashion, Home Decor, Technology, etc.) She currently consults on our digital marketing & PR efforts. She helped create and co-moderate our first podcast on MOG-AD and has supported many of our projects, including blog and newsletter articles, website development, and social media management. As an extracurricular passion of hers, she completed a theatre & acting intensive at the American Academy of Dramatic Arts in New York City, and enjoys being involved in the entertainment industry in her spare time.

Chief Media Officer
Advisory Board Member

Jim Broutman

Jim was a publicist in Los Angeles for 17 years. In 2016, at the peak of a second career, he was struck with Transverse Myelitis (TM) and, at the time, what doctors thought were two Multiple Sclerosis (MS) lesions (he now has six lesions).  This episode affected his ability to walk, caused memory issues and other various side effects. Eventually, he recovered his ability to walk, but was left with memory issues and the other side effects. These remaining issues, especially those affecting memory, caused him to be permanently disabled and say goodbye to his career.  A year later, he developed Optic Neuritis (ON) and was officially diagnosed with MS for which he started treatment. Three months later, his blood work was sent to the Mayo Clinic by his local neurologist and tested positive for MOG, which subsequently ruled out MS.  He was able to get an appointment with Dr. Pittock, the head of neurology at Mayo, and now refers to him as “My God and Doctor” (in partnership with his local neurologist).  Jim is more than happy to be a guinea pig for Dr. Pittock’s research.  Today, he uses no preventive treatment and Jim’s titer level was and still is 1:1000.  To support Dr. Pittock’s research to find a cure, Jim has set up his own foundation with Mayo, which can be found on their website. 

Director of Adult Research Advocacy
Advisory Board Member

Chuck Bies

Chuck recently retired from a 35-year career in information technology management.  Chuck joined The MOG Project in late 2019 after being diagnosed with MOG-AD in January 2019 which included a temporary loss of vision caused by Optic Neuritis.  As an advocate for The MOG Project, Chuck is focusing on aiding doctors in their research efforts for improved treatment options and ultimately a cure. He lives in Minneapolis, MN with his wife Susan.  He has two grown-up children, Brian and Katie.

Social Media & Community Outreach Specialist
Advisory Board Member

Diana Lash

Diana lives in Nevada, near beautiful Lake Tahoe with her husband, Kenny and their 2 daughters, Kennedy and Kylee. At age 12, her youngest daughter, Kylee, was diagnosed with Optic Neuritis in April 2018 and later MOG-AD. Diana joined The MOG Project in early 2019. Her goal is to spread awareness and advocate for this rare disease through her work with The MOG Project social media outlets on Facebook and Instagram.

Australian Ambassador & Medical Professional Outreach Specialist
Advisory Board Member

Jenny Khazen

In November 2014, Jenny had her first episode of simultaneous Bilateral Optic Neuritis (BON) which left her blind and hospitalized with a ‘suspected autoimmune aetiology’ cause for her diagnosis from a clinically and radiologically isolated presentation. Jen vowed that if her vision returned, she would pursue her dream as a Primary school teacher in which it did. In August 2019, she suffered a further episode of (UON) and a relapsing MOGAD diagnosis was given to her in March, 2020 when both her CSF and serum returned positive for the MOG antibody and her relapses continued. 

Jenny joined the team to use her expertise in Mathematics to collect, organize and analyze data, her creativity and research skills to collaborate on projects and expand our social media networks, and globally connect neurologists and researchers around the world. Jen is a Primary school teacher in Sydney, Australia who has been educating kids since 2018. She is a strong advocate for little children, particularly those who have underlying health conditions. 

Support Group Leaders
Lil' Hummingbird Nest

Dawn & Brian Groves

Dawn and Brian Groves are parents to three girls and live in Stafford, VA. Their middle daughter was diagnosed with MOG-AD at 7 years old in the Fall of 2020. Trying to rapidly find and absorb as much information as possible about their daughter’s disease, they came across SRNA and attended a support group. As helpful as the group was, they realized the need for a group to support the unique needs of parents and caregivers of pediatric MOG-AD patients. After getting connected with The MOG Project, they asked Julia if a support group could be started. Dawn & Brian are thankful for the platform provided by The MOG Project to come alongside other families working through similar diagnoses with their children.

Education Consultant & Advocacy Specialist
Support Group Leader
Lifting the MOG Fog

Becca Salky

Rebecca (Becca) Salky has had MOG since she was 4 years old, although she didn’t get the official diagnosis until she was 22. She knows what it’s like to live in uncertainty and to feel very alone in navigating the world of MOG. As a result, she decided to host support groups for young adults, in an effort to form a community of those diagnosed with MOG—a place where people can learn about the disease, as well as its symptoms, side effects, and treatments.

She is a nurse by training, currently working as a Clinical Research Coordinator at the Neuroimmunology Clinic and Research Laboratory at Massachusetts General Hospital. She focuses on helping to spread awareness and lead clinical trials to find better diagnostic tools and treatments for MOG. Members of the support group she has been hosting for the past year tell her it’s a very meaningful experience for them and she has loved building a strong community of young adults dealing with similar life challenges. She hopes that anyone suffering from MOG (or MOG-like symptoms) will join her group!  

MOG Project Champion
MOG-AD Advocate

Pamela Fontanez

Pamela, is a loving and caring homemaker and mother who home-schools their two children, Israel and Isabel, a MOG-AD patient. She loves helping others and is a dedicated advocate for our cause, working along with her husband Peter.

MOG Project Champion
MOG-AD Advocate

Lisa Kovanda

Lisa is a multi-published author, screenwriter, filmmaker, speaker, and writing educator, from Nebraska by way of Tehran. She spent over twenty years in the nursing profession, and over a decade as a retail manager. She was diagnosed with MOG disease after an episode of optic neuritis in 2013. Although MOG has forced her into disability, she still pursues artistic endeavors, writing, and being an extremely amateur aviation apprentice. Her 13 grandchildren are the light of her life.

Johns Hopkins Hospital
Johns Hopkins University

Elias Sotirchos, MD

Dr. Sotirchos is an Assistant Professor of Neurology at Johns Hopkins University and Director of the Johns Hopkins Neuromyelitis Optica Center. He earned his medical degree from the National and Kapodistrian University of Athens and subsequently completed his Osler internship and neurology residency training at the Johns Hopkins Hospital, serving as chief resident in his final year. He then pursued advanced clinical and research training in neuroimmunology at Johns Hopkins as a National Multiple Sclerosis Society Sylvia Lawry Fellow.

Dr. Sotirchos specializes in the diagnosis, management and treatment of neuroimmunological conditions that involve the central nervous system, including MOG-IgG associated disease (MOGAD), neuromyelitis optica spectrum disorder (NMOSD), and multiple sclerosis (MS). His research involves the application of imaging techniques, including retinal optical coherence tomography (OCT) and brain magnetic resonance imaging (MRI), to study these conditions. His work especially focuses on visual pathway involvement in neuroimmunological conditions, and aims to characterize mechanisms of neurodegeneration and to identify novel biomarkers for predicting and monitoring the disease course and therapeutic response.

Stanford Hospital
Stanford University

May Han, MD

Dr. Han is a board-certified neurologist and a clinician-scientist who specializes in multiple sclerosis and central nervous system demyelinating diseases. She was born and raised in Burma (Myanmar) and received her medical degree at the Institute of Medicine (1), Rangoon. She did her post-doctoral fellowship training in protein and membrane lipid biochemistry under the mentorship of Dr. John Glomset at the Howard Hughes Medical Institute (University of Washington, Seattle).
She completed Neurology residency at University of Washington-affiliated hospitals and a fellowship in Neuroimmunology (MS) at Stanford with Dr. Lawrence Steinman. She joined the Stanford Neurology department and MS Center in 2009.
Her research focuses on utilizing Systems Biology approach (genomics, transcriptomics and proteomics) to identify targets for therapy in MS and NMO. Dr. Han is also an attending physician at the Neuroimmunology clinic and at the Stanford Hospital.

Brigham and Women's Hospital
Harvard University

Tanuja Chitnis, MD, FAAN

Dr. Chitnis is a Professor of Neurology at Harvard Medical School, Senior Neurologist at Brigham and Women’s Hospital and Massachusetts General Hospital, and Senior Scientist within the Ann Romney Center for Neurologic Diseases at Brigham and Women’s Hospital where she created the Translational Neuroimmunology Research Center focused on bringing bench discoveries to clinical trials for MOG-AD, multiple sclerosis and neuromyelitis optica spectrum disorders. She created and serves as the Director of the Partners Pediatric MS Center at the Massachusetts General Hospital for Children.
She has published over 250 scientific studies, including key publications on MOG-AD phenotypes and biomarkers. She receives grant funding from the Department of Defense, NIH, National MS Society and the Guthy Jackson Charitable Foundation. She is the recipient of several awards including the Joseph Martin Award for Clinical Research in 2019 from the Scientific Advisory Council at Massachusetts General Hospital, and the 2018 Milestones Award from the National MS Society. In addition to her mentioned positions, she is also a Director of the Translational Neuroimmunology Research Center, The CLIMB Study, and Partners Multiple Sclerosis Center at Brigham and Women’s Hospital as well as a Co-Director for the Partners Multiple Sclerosis Center Fellowship Program.

UT Southwestern Medical Center

Lauren Tardo, MD

Dr. Tardo is an Instructor in the Neuroimmunology division of the Department of Neurology at UT Southwestern Medical Center. She completed medical school at the University of Mississippi School of Medicine and completed her adult neurology residency at UT Southwestern Medical Center. Dr. Tardo remained at UT Southwestern for a fellowship in Neuroimmunology and Multiple Sclerosis with Dr. Benjamin Greenberg. She was trained to diagnose and manage both adult and pediatric patients with anti-MOG antibody associated disease. She is actively engaged in translational research and clinical trials within the Neuroimmunology Section. Dr. Tardo is board certified in neurology by the American Board of Psychiatry and Neurology.

Children's Hospital of Philadelphia

Brenda Banwell, MD, FRCPC, FAAN

Dr. Brenda Banwell is Professor of Pediatrics and Neurology, Perelman School of Medicine, University of Pennsylvania (PENN), and Chief of Child Neurology, Children’s Hospital of Philadelphia (CHOP). She also serves as the Co-Lead of the NeuroImmune Program, an innovative age-span program that focuses on multiple sclerosis, MOG-associated disorders and other acquired inflammatory neurological conditions in children and adults.

Dr. Banwell has over 300 scientific publications and has chaired over 50 international courses focused on pediatric demyelinating diseases. Dr. Banwell leads a multisite North American prospective study of clinical outcomes, genetics, immunology, and neuroimaging features of MS in children. She has published studies focused on the clinical characteristics of MOG related disease in children, and on the MRI features of this disease.

Dr. Banwell also serves as the Chair of the International Pediatric Multiple Sclerosis Study Group, and as the Chair of the International Medical and Scientific Advisory Board of the Multiple Sclerosis International Federation. More recently, Dr. Banwell has been asked to serve as a Co-Lead of the MOG International Diagnostic Criteria Working Group, and is a member of the MOG International Consortium.

Dr. Banwell studied medicine at the University of Western Ontario, followed by residencies in pediatrics at the University of Western Ontario and Child Neurology at the University of Toronto. She then pursued a Neuromuscular Fellowship at the Mayo Clinic, Rochester, MN. Dr. Banwell rose to the rank of Full Professor at the University of Toronto prior to relocating to The Children’s Hospital of Philadelphia in 2012. Banwell remains as an Adjunct Senior Scientist in the Research Institute at The Hospital for Sick Children, Toronto Canada.

Mayo Clinic

John Chen, MD, PhD

Dr. Chen is a Professor of Ophthalmology and Neurology at the Mayo Clinic in Rochester, Minnesota. He earned his medical and PhD degrees from the University of Virginia and subsequently completed his Ophthalmology residency and Neuro-Ophthalmology fellowship training at the University of Iowa where he was selected as a Heed fellow. He joined the faculty at the Mayo Clinic in 2014 where he works closely with the Neuroimmunology Department and has a special interest in optic neuritis, especially in the setting of MOG antibody-associated disease (MOGAD).
Dr. Chen specializes in the diagnosis, management and treatment of optic neuritis. He works closely with Drs. Pittock and Flanagan, Neuroimmunologists at the Mayo Clinic, to better describe the clinical manifestations of MOGAD. He has expertise in optical coherence tomography and how it relates to optic neuritis, which will be pivotal in understanding this tool as a biomarker of MOGAD optic neuritis outcomes and disease progression. In conjunction with the Neuroimmunology Laboratory, he aims to identify other biomarkers of autoimmune vision loss.

Mayo Clinic

Sean Pittock, MD

Dr. Pittock is a Professor of Neurology, Director of the Neuroimmunology Laboratory and the Center for MS and Autoimmune Neurology at the Mayo Clinic. His expertise is in the laboratory and clinic
based diagnosis and management of immune mediated neurological disorders. He is considered
a leader in the field of glial autoimmunity as it pertains to inflammatory CNS demyelinating
diseases including MS. He currently serves as the chair of the Autoimmune Neurology Section at
the American Academy Neurology. His research is translational, and is focused on

1) the identification of novel biomarkers of autoimmune neurological disease (antibodies to AQP4, GFAP, MAP1B-IgG, Kelch11);
2) the clinical application of laboratory-based tests in diagnosis and outcome prediction for patients with autoimmune and paraneoplastic neurological disorders;

3) optimizing the clinical management of autoimmune and paraneoplastic neurological disorders. 


He currently directs the Mayo Clinic Neuroimmunology Laboratory which tests
approximately 200,000 patients for comprehensive neural antibody profiles (CAP and New York
State certified) pertinent to inflammatory CNS disorders. As Director of the Center for MS and
Autoimmune Neurology at Mayo Clinic, he has assisted in building the largest biorepository of
blood and cerebrospinal fluid samples from MS and inflammatory CNS disorders in the world.

Our Laboratory also provides testing for biomarkers of type 1 diabetes allowing collection and storage of more than 1000 serum samples. His research has been supported by Mayo Clinic, NIH (R01) and the Guthy-Jackson Charitable Foundation. He has published more than 300 peer reviewed papers in the field of MS and Autoimmune Neurology. He recently co-edited the first
textbook of Autoimmune Neurology.

Mayo Clinic

Eoin P. Flanagan, M.B., B.Ch.

Dr. Flanagan is a Professor of Neurology and Consultant in the departments of Neurology and Laboratory Medicine and Pathology at the Mayo Clinic (Rochester, MN). He did medical school at University College Dublin in Ireland in 2005 and later pursued neurology residency and neuroimmunology fellowship at Mayo Clinic (Rochester, MN). He received a Master’s degree in clinical and translational science at Mayo Clinic and is principal investigator on an NIH RO1 grant studying the epidemiology, pathology, radiologic features and outcome of Myelin Oligodendrocyte Glycoprotein antibody associated disorder (MOGAD). His clinical expertise and research is focused on MOGAD, aquaporin-4 antibody positive neuromyelitis optica spectrum disorder (NMOSD) and transverse myelitis. He directs teaching courses at the American Academy of Neurology on autoimmune encephalitis and myelitis. He works in the Autoimmune and Multiple Sclerosis Neurology Clinics and the Neuroimmunology Laboratory at the Mayo Clinic. He also has an interest in paraneoplastic neurologic disorders, autoimmune encephalitis and the epidemiology of MOGAD, NMOSD and autoimmune encephalitis.

Chidren's Hospital Los Angeles
University of Southern California

Jonathan Santoro, MD

Dr. Santoro serves as the Director of the Neuroimmunology and Demyelinating Disorders Program at Children’s Hospital Los Angeles and as an Assistant Professor of Neurology at the Keck School of Medicine at the University of Southern California. Dr. Santoro completed his undergraduate, masters, and medical degrees at Tulane University. He subsequently completed residencies in pediatrics and child neurology at Stanford University School of Medicine and obtained sub-specialty training in neuroimmunology and pediatric multiple sclerosis at the Massachusetts General Hospital and Boston Children’s Hospital. Dr. Santoro’s pediatric-specific program is one of the largest on the west coast and utilizes a multi-disciplinary team model that optimizes patient outcomes and improves access to sub-specialty care. Dr. Santoro leads multiple clinical research studies designed at identifying endocrine biomarkers of disease in neuroimmunologic conditions as well as evaluation of specific neurocognitive disease phenotypes. Dr. Santoro is a long-standing advocate for persons with disabilities and has lobbied locally in California and on Capitol Hill through the American Academy of Neurology and the American Medical Association.

University of Louisville

LIsa Ryan, PhD

Dr. Ryan is Associate Professor of Oral Immunology and Infectious Diseases at the University of
Louisville School of Dentistry and holds a joint Courtesy Assistant Professor appointment at the University of Florida College of Medicine. She is an immunologist and toxicologist who has led research on the effects of environment and nutrition on the innate immune system and its role in viral infections such as influenza and Herpes Simplex virus. In addition to faculty positions at the U.S Environmental Protection Agency (U.S. EPA), Rutgers University Health Sciences Center, the University of Florida, and the University of Louisville, she has served as a scientific policy advisor in the U.S. EPA’s Office of Research and Development Office of Science Policy.
She served on many grant review committees for the National Institutes of Health, the Department of Defense’s Congressionally Directed Medical Research Program, the UK’s Medical Research Council, the Italian Ministry of Health, and private foundations.

Dr. Ryan received her Ph.D. from the University of Pittsburgh in immunotoxicology and inhalation toxicology and was a postdoctoral fellow in pulmonary immunology with Harvard Medical School at Massachusetts General Hospital in Boston. She also studied microbiology, receiving her M.S. in medical microbiology from West Virginia University and a B.S. in microbiology from Penn State University. She also has industry experience in risk assessment with inhaled and skin-applied consumer products, working as Associate Manager for Inhalation Toxicology and the Established Portfolio for Reckitt.

University of Louisville

Gill Diamond, PhD

Dr. Gill Diamond received his B.A. in biochemistry from the University of Pennsylvania, and his Ph.D. in genetics from the Hebrew University of Jerusalem. He did his postdoctoral research in the Division of Human Genetics and Molecular Biology at the University of Pennsylvania in the Children’s Hospital of Philadelphia, where he helped pioneer the field of antimicrobial peptides. He was a faculty member at the University of Medicine and Dentistry of New Jersey (a part of Rutgers University) and at the University of Florida.

Currently, he is a Professor in the Department of Oral Immunology and Infectious Diseases at the University of Louisville. His research focuses on innate immunity, and ways to enhance our own immunity to infectious diseases, as well as the development of novel antibiotics and antiviral agents.

Oxford University

Jackie Palace, BM, FRCP, DM

Dr Jacqueline Palace is a consultant neurologist in Oxford and a Professor in the Nuffield Department of Clinical Neurosciences, Oxford University. She is involved in running a national service for neuromyelitis optica and a national service for congenital myasthenic syndromes (CMS) and a lead of the Oxford Multiple Sclerosis group. Her research interests covers MS, NMO, CMS and myasthenia gravis and includes clinical treatment trials, immunological studies, pathology, biomarkers, genetics and imaging studies. She was the clinical lead for the National MS Risk Sharing Scheme which assessed the long-term effectiveness for disease modifying agents in multiple sclerosis, is a board member for the European Charcot Foundation, on the steering committee for MAGNIMS and was the Oxford lead for the European Rare Network for Neuromuscular diseases until Brexit.

Kid's Neuroscience Centre
University of Sydney

Sudarshini Ramanathan, MD, PhD

Associate Professor Darshi Ramanathan is a neurologist and clinician-scientist, with subspecialty expertise in neuroimmunology. She completed her neurology specialisation (FRACP), and was awarded her PhD on the clinical and immunophenotypic characterisation of MOG antibody associated diseases (MOGAD) through the University of Sydney. She undertook a postdoctoral fellowship with the Oxford Autoimmune Neurology Group at the John Radcliffe Hospital and University of Oxford, where she developed expertise in B cell immunology and neuroscience. She has been awarded a number of prestigious fellowships including an NHMRC funded PhD, an NHMRC Neil Hamilton Fairley Early Career Fellowship, and most recently, an NHMRC Investigator Grant. Dr. Ramanathan is a staff specialist neurologist at Concord Hospital where she looks after patients with autoimmune neurological disorders.
In 2013, Associate Professor Ramanathan established and has since been lead investigator of the Australian and New Zealand MOG Study Group, which encompasses over 150 neurologists, immunologists, and ophthalmologists from over 45 centres in the Asia Pacific region. She works closely with Professor Russell Dale and Associate Professor Fabienne Brilot, and leads the evaluation of a cohort of over 500 MOGAD pediatric and adult patients. She leads the Translational Neuroimmunology Group at the University of Sydney. Her clinical and fundamental science research program is focused on understanding disease pathogenesis and improving the diagnosis and treatment of autoimmune neurological disorders including MOGAD, neuromyelitis optica spectrum disorder, autoimmune encephalitis, autoimmune muscle disease, and inflammatory neuropathies.

Kid's Neuroscience Centre
University of Sydney

Fabienne Brilot, PhD

Prof Fabienne Brilot obtained her PhD in Belgium and at the JD Gladstone Institutes, UCSF, USA. She then became postdoctoral fellow under the mentorship of Professor Christian Munz (University of Zurich, Switzerland) at the Browne Center for Immunology and Immune Diseases headed by late Professor Ralph Steinman (Nobel Prize for Medicine 2011) at the Rockefeller University, USA. She was recruited at the Children’s Hospital at Westmead in Sydney in 2007 where she started the Brain Autoimmunity Group.
Fabienne is Principal Research Fellow at the University of Sydney, and her research focuses on neuroimmunological brain disorders such as demyelinating disorders and movement and psychiatric disorders. Her group aims to discover biomarkers and explores the autoimmune response in patients to improve their diagnosis and treatment. Through with many collaborations with paediatric and adult neurologists, her team has contributed to the characterization of MOG antibodies and the diagnosis of MOGAD.

Fabienne is a member of the International Society of Neuroimmunology (ISNI) International Advisory board. She is the Secretary of the International Women in Multiple Sclerosis (iWiMS) network. She also is the President of Neuroimmunology Australia, was the Scientific Chair of the 14th International Congress of Neuroimmunology (ISNI) 2018, and is the co-convenor of the 3rd Asia-Pacific School of Neuroimmunology (APSNI) in 2021.

Kid's Neuroscience Centre
University of Sydney

Russell Dale, MD, PhD

Professor Russell Dale is a Professor of Paediatric Neurology at the Children’s Hospital at Westmead and University of Sydney. His primary interests are in autoimmune neurology and the role of the immune system in neurodevelopmental and neuropsychiatric disorders. He is Head of School and Head of the Speciality of Child and Adolescent Health at the University, and clinical director of the Kids Neuroscience Centre, a research centre of 100 researchers. He has published 270 peer reviewed publications, cited 17,000 times on Google Scholar, H factor 67, and has published some important work on the clinical and radiological phenotyping and treatment of autoimmune and inflammatory neurological disorders. He works closely with Dr Darshi Ramanathan and A/Prof Fabienne Brilot on autoantibody neurology syndromes in Sydney, including MOGAD.

University of Sassari

Elia Sechi, MD

Dr. Sechi is a neurology consultant at the Department of Medical, Surgical and Experimental Sciences at the University of Sassari (Italy), where he completed medical school and neurology residency. He was Assistant Professor of Neurology at the Mayo Clinic in Rochester (MN, USA), where he undertook a 3-year post-doc Neuroimmunology Research Fellowship and received a Master’s Degree in Clinical and Translational Sciences. His clinical and research interest is in immune-mediated disorders of the CNS, with specific focus on CNS demyelinating disorders, including MOG-IgG-associated disorders (MOGAD) and AQP4-IgG-positive neuromyelitis optica spectrum disorders (NMOSD). He is also interested in disorders of the spinal cord (myelopathies).

MOG Project Champion
MOG-AD Advocate

Dana Yates

Dana is an accomplished marketer with over 20 years’ experience project managing teams for complex website builds, mobile apps and social media marketing. Dana was diagnosed with MOG-AD in 2020 following a 30-day fever of unknown origin. In search of information on the disease, treatments, and prognosis, she found The MOG Project and began communicating with the team, offering contributions for new projects in addition to supporting the MOG-AD social media community. In her spare time, Dana is launching an art party business and hopes to open an art studio teaching arts and crafts for all abilities. She also enjoys creating her own art, making jewelry, and is working on a novel.

MOG Project Champion
Public Relations

Eileen Coyne

Eileen Coyne is mother to three boys, the youngest of whom was diagnosed with MOG-AD in March 2020 at age 10. Desperate to learn more about this rare disease, Eileen came across The MOG Project online and found it to be a life-line at a difficult time. A director at a national public relations agency, Kimball Hughes Public Relations, Eileen recognized that winning the attention of the media would be key to spreading awareness about MOG-AD and the incredible work done by The MOG Project. She introduced The MOG Project to the executive team at her agency and quickly sprang to action assembling a team and crafting a detailed media plan with the goal of raising the profile of MOG-AD to educate patients, caregivers and the public at-large. Since then, that partnership has led to high-profile media placements, including a syndicated piece in The Washington Post, a segment on the local NBC television affiliate in Washington D.C., and segments on international podcasts that have helped The MOG Project gain new attention from leading doctors in the space, patients, and caregivers, as well as major pharmaceutical players, grant makers, donors, sponsors and more.

MOG Project Champion
Public Relations

James McKinsey

James McKinsey is a seasoned public relations manager with experience working with nonprofit organizations and prior volunteer experience with groups like the Boy Scouts of America and the Connecticut Humane Society. James was introduced to The MOG Project by his colleagues at  Kimball Hughes Public Relations and has played a key role in building a strategy and implementing tactics to raise awareness of MOG-AD by sharing The MOG Project’s mission and story with US and international media. Recognizing the need to capture the media’s attention, James crafted a detailed media plan, drafted and developed press releases, conducted outreach with leading doctors in the MOG-AD space and worked tirelessly to build contacts with key media. Notably, James led Kimball Hughes Public Relation’s efforts to secure a medical mystery column featuring the MOG-AD journey of Julia Lefelar, The MOG Project’s Executive Director, with syndicated author Sandra Boodman in The Washington Post.

MOG Project Champion
College Intern

Chelsea Ednie

Chelsea is a Junior at WVU studying marketing, with a minor in communications and an emphasis in professional sales. She hopes to work in sales technology & software operations. She has worked many summers at The MOG project, helping at events, coordinating social media, and her latest project, that will help us gain better understanding on how we can serve the MOGAD community through surveys and marketing data analytics. Chelsea has been with us since 2019 and is still going strong! 

Massachusetts General Hospital
Harvard University

Michael Levy, MD, PhD

Dr. Levy is an Associate Professor in Neurology who was recently recruited to lead the new Neuroimmunology Division at the Massachusetts General Hospital. His mission is to build a combined clinical and research neuroimmunology program to develop therapies for patients with autoimmune diseases of the central nervous system. Dr. Levy moved from Baltimore, MD, where he was one of the faculty at Johns Hopkins University since 2009 and Director of the Neuromyelitis Optica Clinic.

Clinically, Dr. Levy specializes in taking care of children and adults with rare neuroimmunological diseases including neuromyelitis optica, transverse myelitis, MOG antibody disease and acute disseminated encephalomyelitis. In addition to four monthly clinics, Dr. Levy is the principal investigator on several clinical studies and drug trials for these conditions.

In the laboratory, Dr. Levy’s research focuses on four main areas:
1. Development of animal models of neuromyelitis optica (NMO) with the goal of tolerization as a sustainable long term treatment: His team generated a mouse model of NMO based on pathogenic T cells reactive against the aquaporin-4 water channel. Now, they are using this mouse model to create a tolerization therapy to desensitize the immune response to aquaporin-4.
2. Genetic basis of transverse myelitis: His team discovered a genetic mutation in VPS37a found in a group of patients with a familial form of transverse myelitis (TM). To understand how this gene is involved in this immune process, they generated a mouse model with this mutation.
3. The immunopathogenesis of MOG antibody disease: This may depend on a subset of T cells called gamma/delta T cells. These specialize T cells react to MOG in mouse models and attack the central nervous system. In addition to understanding why and how these T cells are involved in MOG antibody disease, they are developing a treatment to target these cells.
4. Biomarker assays for other autoimmune diseases of the central nervous system: They are developing assays that detect autoreactive T cells in NMO and MOG antibody disease. In parallel, they are screening for novel antibodies to glial cells in related disorders such as encephalitis and optic neuritis.

Mayo Clinic

Cristina Valencia Sanchez, MD, PhD

Cristina Valencia-Sanchez, MD, PhD, is an Assistant Professor of Neurology at Mayo Clinic in Arizona. She is originally from Spain, where she received her medical degree. She completed her neurology residency and multiple sclerosis fellowship at Mayo Clinic Arizona, followed by an autoimmune neurology
fellowship at Mayo Clinic Rochester.
Dr. Valencia-Sanchez is a Senior Associate Consultant at the Multiple Sclerosis and Autoimmune Neurology division at Mayo Clinic Arizona. Her clinical and research focus includes immune-mediated disorders that involve the central nervous system, such as MOG-IgG associated disease (MOGAD), neuromyelitis optica spectrum disorders (NMOSD), multiple sclerosis, autoimmune encephalitis and paraneoplastic neurological disorders.
Dr. Valencia-Sanchez is involved in ongoing clinical trials for autoimmune neurological conditions
including MOGAD.
Dr. Valencia-Sanchez is an editorial board member for the American Academy of Neurology magazine
“Brain Life”, in Spanish.

Great Ormond Street Hospital
University College London

Yael Hacohen, MD, PhD

Yael Hacohen is a senior lecturer in paediatric neurology at University College London and a consultant paediatric neurologist at Great Ormond Street Hospital, London. Yael completed her doctoral studies in 2014, in the Nuffield Department of Clinical Neuroscience (NDCN) at Oxford University, where she studied children with autoimmune encephalitis and characterised their clinical and immunological (autoantibody) phenotypes. Yael’s main research interest is precision medicine in acquired demyelinating syndromes such as MOGAD and paediatric multiple sclerosis

Great Ormond Street Hospital
University College London

Kshitij Mankad MRCP, FRCR, PG Dip

Kish Mankad is a Clinical Lead for Pediatric Neuroimaging at Great Ormond Street Hospital in London, with a particular interest in ‘impact radiology’ where diagnostics can be timely, precise, and personalized. His primary academic interests are neuroinflammation, neurooncology, and epilepsy disorders in children. Beyond Medicine, Kish is an educationist and has set up several teaching and training platforms, particularly the Society of Pediatric Neuroimaging, aimed at training healthcare professionals globally. He also has a significant interest in quality improvement in healthcare and is an expert in Lean Six Sigma. 

University of South Florida
Muma College of Business

Michael Diamond

Michael Diamond is a graduating senior at the University of South Florida Muma College of Business. He will graduate with a degree in Marketing. With a passion for acting and his degree in marketing, Michael’s goal is to apply those combined skills in the entertainment industry. Michael joined The MOG Project in February 2023 and will be working on a marketing plan specifically addressing awareness campaigns and fundraising opportunities.